Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitravatinib + Tislelizumab in Metastatic Uveal Melanoma With Liver Metastases
NCT05542342Phase 2Completed
- Start
- Sep 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sitravatinib and tislelizumab in Uveal melanoma (UM). Primary endpoint: Objective Response Rate at 1 year. Started Sep 2022; status: completed.
02
Drugs
sitravatinibtislelizumab
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT05542342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05542342.